Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:36:33 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:BIIB from 2023-05-04 to 2024-05-03 - 33 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 07:30U:BIIBNews ReleaseBiogen Reports Progress on Corporate Responsibility Priorities
2024-03-31 19:30U:BIIBNews ReleaseEisai Completes Submission of LEQEMBI(TM) (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
2024-03-06 07:31U:BIIBNews ReleaseNew Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA(TM) (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
2024-03-04 16:16U:BIIBNews ReleaseBiogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD(TM)) 2024 Annual Meeting
2024-02-23 07:00U:BIIBNews ReleaseBiogen's QALSODY(TM) (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
2024-02-12 16:06U:BIIBNews ReleaseBiogen Received European Commission Approval for SKYCLARYS ‚ ® (omaveloxolone), the First Therapy to Treat Friedreich ¢ € ™s Ataxia
2024-01-31 07:30U:BIIBNews ReleaseBiogen to Realign Resources for Alzheimer's Disease Franchise
2023-12-19 07:30U:BIIBNews ReleaseCentralized Marketing Authorizations of Generic Versions of TECFIDERA ‚ ® are Revoked by the European Commission
2023-12-15 09:05U:BIIBNews ReleaseCHMP Issues Positive Opinion for Biogen ¢ € ™s SKYCLARYS ‚ ® (omaveloxolone), the First Therapy to Treat Friedreich ¢ € ™s Ataxia, a Rare Neurodegenerative Disease
2023-12-14 06:30U:BIIBNews ReleaseZURZUVAE ¢ „ ¢ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
2023-12-14 06:30U:BIIBNews ReleaseZURZUVAE ¢ „ ¢ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
2023-11-06 07:30U:BIIBNews ReleaseBiogen Appoints Monish Patolawala to its Board of Directors
2023-10-25 17:26U:BIIBNews ReleaseEisai Presents New LEQEMBI ‚ ® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer ¢ € ™s Disease From Additional Analyses of Clarity AD at The Clinical Trials
2023-10-25 17:25U:BIIBNews ReleaseEISAI PRESENTS NEW LEQEMBI ‚ ® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON AL
2023-10-25 10:51U:BIIBNews ReleaseNew Data from Biogen ¢ € ™s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer ¢ € ™s Disease
2023-10-24 09:30U:BIIBNews ReleaseLEQEMBI ‚ ® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023
2023-10-19 07:30U:BIIBNews ReleaseBiogen to Present New Data at the Clinical Trials on Alzheimer ¢ € ™s Disease (CTAD) 2023 Meeting
2023-09-29 16:06U:BIIBNews ReleaseFDA Approves Biogen ¢ € ™s TOFIDENCE ¢ „ ¢ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA ‚ ®
2023-09-26 09:00U:BIIBNews ReleaseBiogen Completes Acquisition of Reata Pharmaceuticals
2023-09-25 01:03U:BIIBNews ReleaseLEQEMBI ‚ ® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer ¢ € ™s Disease in Japan
2023-09-06 07:30U:BIIBNews ReleaseBiogen Appoints Jane Grogan as Head of Research
2023-08-04 22:42U:BIIBNews ReleaseFDA Approves ZURZUVAE ¢ „ ¢ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
2023-08-04 22:42U:BIIBNews ReleaseFDA Approves ZURZUVAE ¢ „ ¢ ‚  (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
2023-07-28 07:06U:BIIBNews ReleaseBiogen to Acquire Reata Pharmaceuticals
2023-07-19 19:30U:BIIBNews ReleaseEisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
2023-07-19 19:30U:BIIBNews ReleaseEisai Presents Latest Analysis of Lecanemab ¢ € ™s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer ¢ € ™s Association International Conference (AAIC) 2023
2023-07-06 20:00U:BIIBNews ReleaseFDA Grants Traditional Approval for LEQEMBI ‚ ® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
2023-07-06 20:00U:BIIBNews ReleaseFDA Grants Traditional Approval for LEQEMBI ‚ ® (lecanemab-irmb) for the Treatment of Alzheimer ¢ € ™s Disease
2023-06-30 16:06U:BIIBNews ReleaseNew Data at Cure SMA Highlight Potential Benefit of SPINRAZA ‚ ® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
2023-06-12 17:14U:BIIBNews ReleaseBiogen Announces Changes to Its Board of Directors
2023-06-09 18:45U:BIIBNews ReleaseFDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI ‚ ® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
2023-06-09 18:45U:BIIBNews ReleaseFDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI ‚ ® (lecanemab-irmb) for the Treatment of Alzheimer ¢ € ™s Disease
2023-05-15 19:30U:BIIBNews ReleaseHealth Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer ¢ € ™s Disease